Regeneron Pharmaceuticals Q1 2026 Earnings Call Summary
Regeneron Pharmaceuticals reported 19% revenue growth and 15% non-GAAP EPS growth in Q1 2026, driven by strong performance in immunology and oncology. Key products like DUPIXENT and EYLEA HD saw significant growth, and the company announced a $3 billion share repurchase program and a new gene therapy offered for free in the U.S.
Topics: Drug Pricing Earnings EPS Growth Pipeline Milestones R&D Investment Revenue Growth Share Repurchase